13 results about "Mesodermal cell" patented technology

The invention provides an umbilical cord matrigel stem cell culture medium as well as a preparation method and application thereof, and belongs to the technical field of stem cells. Comprising the following raw materials: polyethylene glycol, cane sugar, an exosome composition, a cell factor composition, globulin, tween-80 and a PBS buffer solution. The culture medium can promote the growth of cell mitosis and mesoderm cells, the cells are not prone to deformation in in-vitro culture, the cell clone formation rate retention rate after multiple passage is high, the cells can still keep the characteristics of primary cells after being gradually differentiated, and the culture medium has wide application prospects.

This invention discloses a method for co-culturing and inducing stem cell differentiation into hematopoietic progenitor cells. The method includes the following steps: culturing pluripotent stem cells to obtain embryoid bodies; culturing the embryoid bodies for mesodermal differentiation to obtain mesodermal cells; culturing the mesodermal cells for hematopoietic endothelial differentiation to obtain hematopoietic endothelial cells; and co-culturing the hematopoietic endothelial cells with mesenchymal stem cells to obtain hematopoietic progenitor cells. Through optimization of the culture system, the differentiation efficiency and the number of hematopoietic progenitor cells obtained are significantly improved; by co-culturing mesenchymal stem cells with hematopoietic endothelial cells, the number of hematopoietic progenitor cells is further increased while maintaining high differentiation efficiency and uniform and stable expression of various markers.

The present disclosure relates to a pluripotent stem cell (PSC)-based method to reconstitute axial development in vitro and to a method for producing the same. The present disclosure provides a three-dimensional cellular aggregate, termed ‘axioloids’, generated in vitro from pluripotent stem and composed of mesodermal cells wherein the cellular aggregate is polarized along its antero-posterior axis and its apical-basolateral axis. This cellular aggregate can reconstitute various aspects of somitogenesis and axial development, including axial elongation, segmentation, epithelial somite formation and patterning (formation of one or more somite-like structures), and oscillation of the segmentation clock under somitogenic culture conditions. Axioloids can also be used to derive various cellular lineages and functional cell types and can be used as a platform to model and reconstitute human embryo development, disease and evolution. Axioloids can be further utilized, among other things, for the assessment of the teratogenicity and toxicology of chemical compounds, the production and testing of cellular therapy products, the study of congenital and acquired human diseases and the evaluation of ongoing and future therapeutic approaches.

A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).

A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).

The present disclosure provides a method for producing lung mesenchymal cells that can be used as feeder cells in induction of alveolar epithelial cells. A method for producing lung mesenchymal cells of the present disclosure includes culturing mesodermal cells in a presence of a mesenchymal cell-inducing factor, KGF, and FGF10 so as to induce differentiation of the mesodermal cells into lung mesenchymal cells.

The present invention provides a method for producing mesodermal lineage cells from an embryoid body, the method comprising: (1) a step for inducing an embryoid body into a differentiated embryoid body in which differentiation into a mesodermal cell lineage is promoted; and (2) a step for determining the solidity of the induced differentiated embryoid body.

This invention relates to a method for preparing cardiac organoids derived from human pluripotent stem cells, comprising: Step A: culturing human pluripotent stem cells (hPSCs) to prepare embryonic bodies with a diameter of 100 μm to 130 μm; Step B: culturing the embryonic bodies prepared in Step A to a diameter of 200 μm to 250 μm; Step C: differentiating the embryonic bodies derived from human pluripotent stem cells with a diameter of 200 μm to 250 μm prepared in Step B into constructs containing mesodermal cells and endoderm cells; Step D: differentiating the constructs containing mesodermal cells and endoderm cells differentiated in Step C into constructs containing cardiomyocytes, fibroblasts, and vascular endothelial cells. Self-organized cardiac organoids (cells); and, step E: culturing and maturing the self-organized cardiac organoids differentiated through step D, wherein the cardiac organoids that have completed the maturation process through step E have cardiomyocytes, fibroblasts, and endothelial cells forming a self-organized structure with a cell ratio of 55 to 65:15 to 30:15.

The present invention relates generally to stem cells, particularly to methods for preventing unwanted cells i.e. off-target cell populations such as stromal cells, non-pancreatic endoderm or pancreatic acinar cells or ductal epithelium. Other type of off target cell populations are mesodermal cell population and / or residual human pluripotent stem cells arising during in vitro differentiation of human pluripotent stem cells into definitive endoderm. The mesodermal cell population formation is inhibited by inactivating in the human pluripotent stem cells one or more genes required for the formation of said cell population. The residual human pluripotent stem cells are eliminated or reduced by culturing the human pluripotent stem cells wherein one or more genes required for the formation of the mesodermal cell population has been inactivated in a medium comprising WNT signalling agonist. The present invention also relates to homogenous cell population of definitive endoderm obtained from such methods.

To provide a method for inducing differentiation of a pluripotent stem cell into a renal precursor cell.SOLUTION: A method includes processes (i) to (vi): (i) culturing a pluripotent stem cell by culture medium containing FGF2, BMP4, GSK-3β inhibitor and retinoic acid or a derivative thereof; (ii) culturing a cell obtained in the previous process by culture medium containing FGF2, GSK-3β inhibitor and BMP7; (iii) culturing a cell obtained in the previous process by culture medium containing FGF2, GSK-3β inhibitor, BMP7 and TGFβ inhibitor; (iv) culturing a cell obtained in the previous process by culture medium containing FGF2, GSK-3β inhibitor, BMP7, activin and ROCK inhibitor; (v) culturing a cell obtained in the previous process by culture medium containing retinoic acid or a derivative thereof and FGF9; and (vi) culturing a cell obtained in the previous process by culture medium containing GSK-3β inhibitor and FGF9, and inducing a renal precursor cell from an intermediate mesodermal cell.SELECTED DRAWING: Figure 1

Disclosed in the present invention are a method for preparing renal progenitor cells and use thereof. The method specifically comprises: inducing differentiation of pluripotent stem cells into an intermediate mesodermal cell stage by means of a GSK-3α / β inhibitor, and then inducing differentiation of cells in the intermediate mesodermal cell stage into a cap mesenchyme stage by using a combination of FGF-2 and an RAR / RXR nuclear receptor agonist, so as to obtain renal progenitor cells having distinct characteristics and potential specific to the cap mesenchyme. According to the method, high-purity and high-quality renal progenitor cells can be obtained without the need for sorting and purification, and the purity can reach 99.9%; the obtained renal progenitor cells have the differentiation potential of kidney-like organs, are basically free of residual PSCs, have the differentiation potential of kidney-like organs, and thus are suitable for clinical cell therapy. Moreover, the method features simple, stable, and controllable operations, facilitating the large-scale preparation of safe, effective, high-purity, and homogeneous renal progenitor cells.

This invention provides a method for differentiating SAN-like cells from pluripotent stem cells in vitro. The method for differentiating SAN-like cells from pluripotent stem cells in vitro includes S1, providing a population of pluripotent stem cells; S2, performing a first contact culture on the pluripotent stem cell population to obtain mesodermal cells; S3, performing a second contact culture on the mesodermal cells to obtain pSHF cells; and S4, performing a third contact culture on the pSHF cells to obtain SAN-like cells. This invention solves at least one of the following problems in the prior art: the induction efficiency of sinoatrial node (SAN)-like cells from pluripotent stem cells is generally low, usually only 30%–50%; and the differentiation cycle is long, the operation steps are cumbersome, and a variety of small molecule additives are required. In addition, the differentiation products contain a large number of NKX2.5 positive atrial or ventricular myocytes, resulting in insufficient purity, which still requires further cell separation and purification.

To provide a new method for producing mesoderm-derived vascular progenitor cells by in vitro differentiation of pluripotent stem cells. Further provided are methods of treating vascular disease, e.g., critical limb ischemia.SOLUTION: A method for producing a population of mesodermal-derived vascular progenitor cells (meso-VPCs) from pluripotent stem cells, comprising culturing pluripotent stem cell-derived mesodermal cells under non-adherent or low-adherent conditions in a medium comprising one or more factors selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs), bone morphogenetic protein-4 (BMP4), and small-molecule inhibitors of transforming growth factor-beta (TGF - β) type I receptor, thereby producing a population of mesodermal-derived vascular progenitor cells. The method includes: SELECTED DRAWING: Figure 3